{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T14:14:44Z","timestamp":1785248084421,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T00:00:00Z","timestamp":1563321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"crossref","award":["2U01-DK065184-06"],"award-info":[{"award-number":["2U01-DK065184-06"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12328-019-01022-5","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T08:03:36Z","timestamp":1563350616000},"page":"276-280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vanishing bile duct syndrome arising in a patient with HIV infection sequentially treated with trimethoprim\/sulfamethoxazole and dapsone"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0556-6543","authenticated-orcid":false,"given":"Pradeep Reddy","family":"Kathi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Tama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray","family":"Ehrinpreis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Mutchnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Westerhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Mowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert John","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,17]]},"reference":[{"key":"1022_CR1","unstructured":"Centers for Disease Control and Prevention. Outpatient antibiotic prescriptions\u2014United States, 2016 [Internet]. 2016. https:\/\/www.cdc.gov\/antibiotic-use\/community\/programs-measurement\/state-local-activities\/outpatient-antibiotic-prescriptions-US-2016.html. Accessed 20 Feb 2019."},{"key":"1022_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3390\/jof4040127","volume":"4","author":"PL White","year":"2018","unstructured":"White PL, Price JS, Backx M. Therapy and management of Pneumocystis jirovecii infection. J Fungi. 2018;4:127.","journal-title":"J Fungi."},{"key":"1022_CR3","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1038\/ajg.2017.215","volume":"112","author":"NP Chalasani","year":"2017","unstructured":"Chalasani NP, Reddy KRK, Fontana RJ, et al. Idiosyncratic drug induced liver injury in African\u2013Americans is associated with greater morbidity and mortality compared to Caucasians. Am J Gastroenterol. 2017;112:1382\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1022_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/MPG.0b013e31821d6cfd","volume":"53","author":"JP Molleston","year":"2011","unstructured":"Molleston JP, Fontana RJ, Lopez MJ, et al. Characteristics of idiosyncratic drug-induced liver injury in children: results from the DILIN prospective study. J Pediatr Gastroenterol Nutr. 2011;53:182\u20139.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"1022_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1590\/S1807-59322009000100014","volume":"64","author":"LC Faria","year":"2009","unstructured":"Faria LC, Resende CC, Couto CA, et al. Severe and prolonged cholestasis caused by trimethoprim-sulfamethoxazole: a case report. Clinics. 2009;64:71\u20134.","journal-title":"Clinics"},{"key":"1022_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1177\/2325957416667486","volume":"15","author":"X Lin","year":"2016","unstructured":"Lin X, Garg S, Mattson CL, et al. Prescription of Pneumocystis jiroveci pneumonia prophylaxis in HIV-infected patients. J Int Assoc Provid AIDS Care. 2016;15:455\u20138.","journal-title":"J Int Assoc Provid AIDS Care."},{"key":"1022_CR7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1136\/pgmj.56.653.202","volume":"653","author":"LA Ogilvie","year":"1980","unstructured":"Ogilvie LA, Toghill PJ. Cholestatic jaundice due to co-trimoxazole. Post Grad Med J. 1980;653:202\u20134.","journal-title":"Post Grad Med J"},{"key":"1022_CR8","doi-asserted-by":"publisher","first-page":"299","DOI":"10.7547\/1000299","volume":"100","author":"M Langlois","year":"2010","unstructured":"Langlois M, Derk F, Belczyk R, et al. Trimethoprim-sulfamethoxazole-induced Stevens\u2013Johnson syndrome: a case report. J Am Podiatr Med Assoc. 2010;100:299\u2013303.","journal-title":"J Am Podiatr Med Assoc"},{"key":"1022_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ijid.2008.12.016","volume":"13","author":"F Hanses","year":"2009","unstructured":"Hanses F, Zierhut S, Sch\u00f6lmerich J, et al. Severe and long lasting cholestasis after high-dose co-trimoxazole treatment for Pneumocystis pneumonia in HIV-infected patients-a report of two cases. Int J Infect Dis. 2009;13:467\u20139.","journal-title":"Int J Infect Dis"},{"key":"1022_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.5223\/pghn.2013.16.4.273","volume":"16","author":"HJ Cho","year":"2013","unstructured":"Cho HJ, Jwa HJ, Kim KS, et al. Urosodeoxycholic acid therapy in a child with trimethoprim-sulfamethoxazole induced vanishing bile duct syndrome. Pediatr Gastroenterol Hepatol Nutr. 2013;16:273\u20138.","journal-title":"Pediatr Gastroenterol Hepatol Nutr"},{"key":"1022_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s005340170002","volume":"8","author":"Y Nakanuma","year":"2001","unstructured":"Nakanuma Y, Tsuneyama K, Harada K. Pathology and pathogenesis of intrahepatic bile duct loss. J Hepatobiliary Pancreat Surg. 2001;8:303\u201315.","journal-title":"J Hepatobiliary Pancreat Surg"},{"key":"1022_CR12","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/hep.28967","volume":"65","author":"HL Bonkovsky","year":"2017","unstructured":"Bonkovsky HL, Kleiner DE, Gu J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements. Hepatology. 2017;65:1267\u201377.","journal-title":"Hepatology"},{"key":"1022_CR13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1034\/j.1399-0012.2003.00040.x","volume":"17","author":"F Zaman","year":"2003","unstructured":"Zaman F, Ye G, Kd A, et al. Case report successful orthotopic liver transplantation after trimethoprim-sulfamethoxazole associated fulminant liver failure. Clin Transplant. 2003;17:461\u20134.","journal-title":"Clin Transplant."},{"key":"1022_CR14","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/0016-5085(92)90346-Z","volume":"102","author":"KV Kowdley","year":"1992","unstructured":"Kowdley KV, Keeffe EB, Fawaz KA. Prolonged cholestasis due to trimethoprim sulfamethoxazole. Gastroenterology. 1992;102:2148\u201350.","journal-title":"Gastroenterology"},{"key":"1022_CR15","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1590\/abd1806-4841.20153408","volume":"90","author":"MV Quaresma","year":"2015","unstructured":"Quaresma MV, Bernardes Filho F, Hezel J, et al. Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent. An Bras Dermatol. 2015;90:S51\u20134.","journal-title":"An Bras Dermatol"},{"key":"1022_CR16","first-page":"1","volume":"05","author":"Tom De Roche LBS","year":"2015","unstructured":"Tom De Roche LBS. The Day Dapsone DRESSed as DILI. J Clin Toxicol. 2015;05:1\u20132.","journal-title":"J Clin Toxicol."},{"key":"1022_CR17","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S0002-9343(96)00008-3","volume":"100","author":"MG Beumont","year":"1996","unstructured":"Beumont MG, Graziani A, Ubel PA, et al. Safety of dapsone as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with allergy to trimethoprim\/sulfamethoxazole. Am J Med. 1996;100:611\u20136.","journal-title":"Am J Med"},{"key":"1022_CR18","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/j.1875-9114.1998.tb03904.x","volume":"18","author":"CD Holtzer","year":"1998","unstructured":"Holtzer CD, Flaherty JFJ, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998;18:831\u20135.","journal-title":"Pharmacotherapy"},{"key":"1022_CR19","first-page":"831","volume":"5","author":"SM May","year":"2017","unstructured":"May SM, Motosue MS, Park MA. Dapsone is often tolerated in HIV-infected patients with history of sulfonamide antibiotic intolerance. J Allergy Clin Immunol Pract [Internet] Am Acad Allergy Asthma Immunol. 2017;5:831\u20133.","journal-title":"J Allergy Clin Immunol Pract [Internet] Am Acad Allergy Asthma Immunol"},{"key":"1022_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.cld.2007.11.007","volume":"12","author":"NS Reau","year":"2008","unstructured":"Reau NS, Jensen DM. Vanishing bile duct syndrome. Clin Liver Dis. 2008;12:203\u201317.","journal-title":"Clin Liver Dis"},{"key":"1022_CR21","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/gut.44.5.731","volume":"44","author":"PG Aithal","year":"1999","unstructured":"Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut. 1999;44:731\u20135.","journal-title":"Gut"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01022-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-019-01022-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01022-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,21]],"date-time":"2024-07-21T02:00:29Z","timestamp":1721527229000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-019-01022-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,17]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["1022"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-01022-5","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,17]]},"assertion":[{"value":"24 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Fontana has received Grant support from Gilead, BristolMyersSquibb, and Abbvie and provided consultation to Sanofi. Dr. Mutchnick has research Grants from Proteus and Gilead and also a Member of Speakers Bureau for Gilead, Abbvie, Intercept and Chronic Liver Disease Foundation. Financial disclosures for the remaining authors: None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for the case report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}